Shattuck Labs stock (US8124231002): Down 5.29% in May 2026 amid biotech volatility

Shattuck Labs (STTK) shares have declined 5.29% in May 2026, trading at $6.62 as of recent data. The biotech firm focuses on immunomodulators, with US investors tracking its Nasdaq listing and clinical pipeline developments.

Shattuck Labs (NASDAQ:STTK), a clinical-stage biotech developing bifunctional fusion proteins, saw its stock drop 5.29% in May 2026, reaching $6.62 per share according to StockTitan as of May 2026. This movement reflects broader volatility in the healthcare sector, where the company operates with a market cap of 507.63 million USD. US investors monitor STTK for its potential in immunotherapy targeting cancer and immune diseases.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Shattuck Labs, Inc.
• Sector/industry: Biotechnology/Healthcare
• Headquarters/country: United States
• Core markets: US, global clinical trials
• Key revenue drivers: Pipeline advancements, partnerships
• Home exchange/listing venue: Nasdaq (STTK)
• Trading currency: USD

Shattuck Labs: core business model

Shattuck Labs develops a class of protein therapeutics based on its proprietary Agonist Redirected Checkpoint (ARC) platform. This technology fuses tumor-enhancing and immune-inhibiting proteins to create bifunctional molecules that activate targeted immune responses against cancer cells. The approach aims to overcome limitations of traditional checkpoint inhibitors by concentrating activity at the tumor site, as described on the company's official website.

Key to the model is SL-1726, the lead candidate in Phase 1 trials for solid tumors and lymphomas. The platform supports multiple assets, positioning Shattuck Labs in the competitive immuno-oncology space relevant to US investors via Nasdaq exposure.

Main revenue and product drivers for Shattuck Labs

Pipeline progress drives value, with SL-1726 advancing in clinical studies. Preclinical data highlight potential in combination therapies. No commercial revenue yet, as the firm remains pre-revenue, funded by equity raises and grants. Recent stock performance at $6.62 reflects investor sentiment on biotech catalysts, per StockTitan May 2026 data.

Partnerships and milestones, such as trial readouts, are primary catalysts. US market relevance stems from high biotech density and investor interest in oncology innovations.

Industry trends and competitive position

Biotech sector faces funding squeezes but immuno-oncology remains hot, with bispecific antibodies gaining traction. Shattuck Labs differentiates via ARC platform's tumor-selective mechanism versus rivals like Regeneron or Roche. US investors benefit from sector leaders' dominance in Nasdaq indices.

Why Shattuck Labs matters for US investors

As a Nasdaq-listed biotech, STTK offers exposure to cutting-edge immunotherapy without overseas risks. Its US headquarters in Durham, NC, align with domestic innovation hubs, appealing to retail portfolios seeking growth in healthcare.

Conclusion

Shattuck Labs continues advancing its ARC platform amid a 5.29% May 2026 share decline to $6.62. Clinical milestones will shape future trajectory in competitive biotech landscape. US investors track Nasdaq volatility and pipeline updates for insights into immunotherapy potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.